Changlong Xu

2.9k total citations · 1 hit paper
43 papers, 2.3k citations indexed

About

Changlong Xu is a scholar working on Molecular Biology, Immunology and Cancer Research. According to data from OpenAlex, Changlong Xu has authored 43 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 8 papers in Immunology and 8 papers in Cancer Research. Recurrent topics in Changlong Xu's work include Advanced biosensing and bioanalysis techniques (5 papers), MicroRNA in disease regulation (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). Changlong Xu is often cited by papers focused on Advanced biosensing and bioanalysis techniques (5 papers), MicroRNA in disease regulation (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). Changlong Xu collaborates with scholars based in China and United States. Changlong Xu's co-authors include Mingzhen Zhang, Didier Merlin, Émilie Viennois, Bo Xiao, Zhan Zhang, Lixin Wang, Yuncheng Zhang, Meena Prasad, Shanthi Srinivasan and Huan Wang and has published in prestigious journals such as Biomaterials, Cancer Research and Chemical Engineering Journal.

In The Last Decade

Changlong Xu

41 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer

2016 719 citations Mingzhen Zhang, Émilie Viennois et al. Biomaterials profile →

Peers

Countries citing papers authored by Changlong Xu

Since Specialization

Citations

This map shows the geographic impact of Changlong Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changlong Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changlong Xu more than expected).

Fields of papers citing papers by Changlong Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changlong Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changlong Xu. The network helps show where Changlong Xu may publish in the future.

Co-authorship network of co-authors of Changlong Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Changlong Xu. A scholar is included among the top collaborators of Changlong Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changlong Xu. Changlong Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A novel targeted long-read sequencing-based preimplantation genetic testing method for α-thalassemia (tlrPGT-α-thal) 2025 ·Journal of Assisted Reproduction and Genetics ·(unknown), (unknown), (unknown), (unknown), Changlong Xu, (unknown), Ying Huang, Ling Zhou, Aiping Mao, Jiaqi Li, Rong Li	0
2	Procyanidin B2 alleviates damage to mouse testicular tissue after freezing by inhibiting oxidative stress and apoptosis 2025 ·Cryobiology ·(unknown), Chunyuan Li, Jian Zhang, Liwen Deng, Hongsong Li, Changlong Xu	2
3	Acrylamide Exposure Impairs Ovarian Tricarboxylic Acid Cycle and Reduces Oocyte Quality in Mouse 2024 ·Environmental Toxicology ·(unknown), (unknown), Ruicheng Li, Wenke Wang, (unknown), (unknown), (unknown), Yifan Yang, (unknown), Hailong Wang, Zhongquan Qi, Changlong Xu, Yu Liu	0
4	Biocompatible carbon dots nanozymes as ROS/RNS modulators for ulcerative colitis alleviation by comprehensively orchestrating intestinal homeostasis 2024 ·Chemical Engineering Journal ·Wenjing Wang, Guangrong Lu, Zhichao Deng, Huanyu Li, Wenfang He, Shouxing Yang, Yuan‐Yuan Zhu, Chenxi Xu, Yujie Zhang, (unknown), Xiaoling Huang, Mingzhen Zhang, Changlong Xu	11
5	Microbial treatment of alcoholic liver disease: A systematic review and meta-analysis 2022 ·Frontiers in Nutrition ·(unknown), (unknown), Min Zhao, (unknown), (unknown), (unknown), (unknown), Changlong Xu, (unknown), Fangyan Wang, Zhanxiong Xue	10
6	Association of Dietary Intake and Biomarker of α-Linolenic Acid With Incident Colorectal Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies 2022 ·Frontiers in Nutrition ·(unknown), Xiaoli Ren, (unknown), (unknown), (unknown), Changlong Xu, Bo Yang	6
7	Effectiveness of Probiotics and Prebiotics Against Acute Liver Injury: A Meta-Analysis 2021 ·Frontiers in Medicine ·Sheng Xu, Min Zhao, (unknown), Zhihua Xu, (unknown), (unknown), (unknown), Sisi Wang, Zhanxiong Xue, Fangyan Wang, Changlong Xu	14
8	A novel fluorescent enhancing platform based on DNA-scaffolded silver nanoclusters for potential inflammatory bowel disease-associated microRNA detection 2020 ·Talanta ·Biyun Fang, Ping Guo, Mei Yang, Yana Ma, Xiangji Yan, Zhenzhen Jia, Wenhui Gao, Sohail Ahmad, Changlong Xu, Cui Liu, Mingzhen Zhang	20
9	Association between the non-HDL-cholesterol to HDL-cholesterol ratio and non-alcoholic fatty liver disease in Chinese children and adolescents: a large single-center cross-sectional study 2020 ·Lipids in Health and Disease ·Shouxing Yang, (unknown), (unknown), Lei Miao, (unknown), Changlong Xu, Zhanxiong Xue, (unknown)	43
10	Novel Compound Heterozygous Mutations in RAG1 in a Patient with Cutaneous Lymphoproliferative Disease 2018 ·Acta Dermato Venereologica ·Changlong Xu, Zhengming Chen, Jie Xiong, Hao Chen, Jianfang Sun	1
11	Association of ulcerative colitis with the imbalance between Th1, Th2 and Th17 cells in the colonic tissues 2017 ·Jiefangjun yixue zazhi ·Hao Wu, (unknown), (unknown), Changlong Xu, Dingyuan Hu, (unknown), Yi Jiang	1
12	A Hyaluronidase-Responsive Nanoparticle-Based Drug Delivery System for Targeting Colon Cancer Cells 2016 ·Cancer Research ·Mingzhen Zhang, Changlong Xu, Liuqing Wen, (unknown), Bo Xiao, Jun Zhou, Yuchen Zhang, Zhan Zhang, Émilie Viennois, Didier Merlin	125
13	Rab11-FIP2 promotes colorectal cancer migration and invasion by regulating PI3K/AKT/MMP7 signaling pathway 2016 ·Biochemical and Biophysical Research Communications ·Changlong Xu, Jianzhang Wang, (unknown), Chenwei Pan, (unknown), (unknown), Shouxing Yang, Bo Zheng	40
14	Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy 2016 ·Molecular Therapy ·Mingzhen Zhang, Bo Xiao, Huan Wang, (unknown), Zhan Zhang, Émilie Viennois, Changlong Xu, Didier Merlin	338
15	Embelin induces apoptosis of human gastric carcinoma through inhibition of p38 MAPK and NF-κB signaling pathways 2016 ·Molecular Medicine Reports ·Changlong Xu, Bo Zheng, (unknown), (unknown), (unknown)	11
16	Plant derived edible nanoparticles as a new therapeutic approach against diseases 2016 ·Tissue Barriers ·Mingzhen Zhang, Émilie Viennois, Changlong Xu, Didier Merlin	247
17	Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer breakdown → 2016 ·Biomaterials ·Mingzhen Zhang, Émilie Viennois, Meena Prasad, Yuncheng Zhang, Lixin Wang, Zhan Zhang, (unknown), Bo Xiao, Changlong Xu, Shanthi Srinivasan, Didier Merlin	719
18	Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy 2015 ·Tumor Biology ·(unknown), Changlong Xu, Bihuan Cheng, Lingxiang Jin, Jie Li, Yuqiang Gong, Wei Lin, Zhenzhen Pan, Chenwei Pan	26
19	Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation 2015 ·European Journal of Pharmacology ·Chenwei Pan, Zhenzhen Pan, (unknown), (unknown), Guangyao Zhou, Wei Lin, Lingxiang Jin, Changlong Xu	95
20	Hyperhomocysteinemia and Related Genetic Polymorphisms Correlate with Ulcerative Colitis in Southeast China 2011 ·Cell Biochemistry and Biophysics ·Yi Jiang, (unknown), Wenxing Wang, (unknown), Changlong Xu, (unknown), (unknown), (unknown), (unknown), Bing Xia	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact